Literature DB >> 16014877

HIV among injection drug users in large US metropolitan areas, 1998.

Samuel R Friedman1, Spencer Lieb, Barbara Tempalski, Hannah Cooper, Marie Keem, Risa Friedman, Peter L Flom.   

Abstract

This article estimates HIV prevalence rates among injection drug users (IDUs) in 95 large US metropolitan areas to facilitate social and policy analyses of HIV epidemics. HIV prevalence rates among IDUs in these metropolitan areas were calculated by taking the mean of two estimates: (1) estimates based on regression adjustments to Centers for Disease Control and Prevention (CDC) Voluntary HIV Counseling and Testing data and (2) estimates based on the ratio of the number of injectors living with HIV to the number of injectors living in the metropolitan area. The validity of the resulting estimates was assessed. HIV prevalence rates varied from 2 to 28% (median 5.9%; interquartile range 4.0-10.2%). These HIV prevalence rates correlated with similar estimates calculated for 1992 and with two theoretically related phenomena: laws against over-the-counter purchase of syringes and income inequality. Despite limitations in the accuracy of these estimates, they can be used for structural analyses of the correlates, predictors and consequences of HIV prevalence rates among drug injectors in metropolitan areas and for assessing and targeting the service needs for drug injectors.

Entities:  

Mesh:

Year:  2005        PMID: 16014877      PMCID: PMC3456049          DOI: 10.1093/jurban/jti088

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  25 in total

1.  Low estimates of HIV seroconversions among clients of a drug treatment clinic in San Francisco, 1995 to 1998.

Authors:  W McFarland; T A Kellogg; B Louie; C Murrill; M H Katz
Journal:  J Acquir Immune Defic Syndr       Date:  2000-04-15       Impact factor: 3.731

2.  Drug-assistance programs funded by Title II of the Ryan White CARE Act: a survey of the states.

Authors:  R J Buchanan; S R Smith
Journal:  AIDS Public Policy J       Date:  1996

3.  Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus.

Authors:  N G Shah; D D Celentano; D Vlahov; V Stambolis; L Johnson; K E Nelson; S A Strathdee
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

4.  HIV prevalence among injection drug users in three Northern California communities.

Authors:  D Longshore; J Annon; M D Anglin
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-10-01

5.  Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996.

Authors:  D C Des Jarlais; T Perlis; S R Friedman; S Deren; T Chapman; J L Sotheran; S Tortu; M Beardsley; D Paone; L V Torian; S T Beatrice; E DeBernardo; E Monterroso; M Marmor
Journal:  Am J Public Health       Date:  1998-12       Impact factor: 9.308

6.  Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment.

Authors:  M D Stein; J Maksad; J Clarke
Journal:  Drug Alcohol Depend       Date:  2001-02-01       Impact factor: 4.492

7.  The risk environment for HIV transmission: results from the Atlanta and Flagstaff network studies.

Authors:  R Rothenberg; J Baldwin; R Trotter; S Muth
Journal:  J Urban Health       Date:  2001-09       Impact factor: 3.671

8.  An HIV prevalence-based model for estimating urban risk populations of injection drug users and men who have sex with men.

Authors:  Spencer Lieb; Samuel R Friedman; Mary Beth Zeni; Dale D Chitwood; Thomas M Liberti; Gary J Gates; Lisa R Metsch; Lorene M Maddox; Tamara Kuper
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

9.  The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users.

Authors:  Carol F Kwiatkowski; Karen Fortuin Corsi; Robert E Booth
Journal:  Addiction       Date:  2002-10       Impact factor: 6.526

10.  Syringe type and drug injector risk for HIV infection: a case study in Texas.

Authors:  William A Zule; David P Desmond; James Alan Neff
Journal:  Soc Sci Med       Date:  2002-10       Impact factor: 4.634

View more
  31 in total

1.  Use of Medicaid data to explore community characteristics associated with HIV prevalence among beneficiaries with schizophrenia.

Authors:  James Walkup; Ayse Akincigil; Donald R Hoover; Michele J Siegel; Shahla Amin; Stephen Crystal
Journal:  Public Health Rep       Date:  2011 Sep-Oct       Impact factor: 2.792

2.  Female and male differences in AIDS diagnosis rates among people who inject drugs in large U.S. metro areas from 1993 to 2007.

Authors:  Brooke S West; Enrique R Pouget; Barbara Tempalski; Hannah L F Cooper; H Irene Hall; Xiaohong Hu; Samuel R Friedman
Journal:  Ann Epidemiol       Date:  2015-02-07       Impact factor: 3.797

3.  Community characteristics associated with HIV risk among injection drug users in the San Francisco Bay Area: a multilevel analysis.

Authors:  Ricky N Bluthenthal; D Phuong Do; Brian Finch; Alexis Martinez; Brian R Edlin; Alex H Kral
Journal:  J Urban Health       Date:  2007-07-27       Impact factor: 3.671

4.  Estimating the prevalence of injection drug use among black and white adults in large U.S. metropolitan areas over time (1992--2002): estimation methods and prevalence trends.

Authors:  Hannah L F Cooper; Joanne E Brady; Samuel R Friedman; Barbara Tempalski; Karla Gostnell; Peter L Flom
Journal:  J Urban Health       Date:  2008-08-16       Impact factor: 3.671

5.  HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002.

Authors:  Barbara Tempalski; Spencer Lieb; Charles M Cleland; Hannah Cooper; Joanne E Brady; Samuel R Friedman
Journal:  J Urban Health       Date:  2008-11-18       Impact factor: 3.671

6.  Neighborhood poverty and injection cessation in a sample of injection drug users.

Authors:  Arijit Nandi; Thomas A Glass; Stephen R Cole; Haitao Chu; Sandro Galea; David D Celentano; Gregory D Kirk; David Vlahov; William W Latimer; Shruti H Mehta
Journal:  Am J Epidemiol       Date:  2010-01-21       Impact factor: 4.897

7.  Sexual HIV/HSV-2 risk among drug users in New York City: an HIV testing and counseling intervention.

Authors:  Marlene Pantin; Noelle R Leonard; Holly Hagan
Journal:  Subst Use Misuse       Date:  2013-03-25       Impact factor: 2.164

8.  Individual and neighborhood correlates of membership in drug using networks with a higher prevalence of HIV in New York City (2006-2009).

Authors:  Abby E Rudolph; Natalie D Crawford; Carl Latkin; James H Fowler; Crystal M Fuller
Journal:  Ann Epidemiol       Date:  2013-03-21       Impact factor: 3.797

9.  Optimal investment in HIV prevention programs: more is not always better.

Authors:  Margaret L Brandeau; Gregory S Zaric
Journal:  Health Care Manag Sci       Date:  2009-03

10.  Multilevel analysis of HIV related risk behaviors among heroin users in a low prevalence community.

Authors:  Huizhen Li; William Goggins; Shui Shan Lee
Journal:  BMC Public Health       Date:  2009-05-12       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.